Concord Biotech Sustainability Profile
Concord Biotech Ltd, a leading biopharmaceutical company headquartered in India, has established itself as a key player in the global biotechnology industry since its inception in 2000. With a strong focus on the development and manufacturing of biopharmaceuticals, the company operates primarily in India and has expanded its reach to various international markets. Specialising in the production of biosimilars and active pharmaceutical ingredients (APIs), Concord Biotech is renowned for its commitment to quality and innovation. The company’s core products include a range of biosimilars that cater to therapeutic areas such as oncology and autoimmune diseases, setting them apart through rigorous research and development processes. Recognised for its significant contributions to the biopharmaceutical sector, Concord Biotech has achieved notable milestones, including successful product launches and strategic partnerships, solidifying its position as a trusted name in the industry.
DitchCarbon Score
How does Concord Biotech's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Concord Biotech's score of 15 is lower than 90% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Concord Biotech's reported carbon emissions
In 2025, Concord Biotech reported total carbon emissions of approximately 12,511 kg CO2e for Scope 1 and 23 kg CO2e for Scope 2. In 2024, the company disclosed significantly higher emissions, with Scope 1 at about 14,340,180 kg CO2e and Scope 2 at approximately 42,409,680 kg CO2e. For the year 2023, emissions were reported at 14,340,180 kg CO2e for Scope 1 and 42,409,680 kg CO2e for Scope 2, with no emissions recorded for Scope 3. Concord Biotech has not set specific reduction targets or initiatives as part of the Science Based Targets initiative (SBTi) or other climate pledges. The company’s emissions data is not cascaded from a parent organisation, indicating that all reported figures are directly from Concord Biotech Limited. Overall, while the company has made strides in emissions reporting, it currently lacks defined reduction commitments or initiatives to address its carbon footprint.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2024 | 2025 | |
|---|---|---|
| Scope 1 | 14,340,180 | 00,000.0 |
| Scope 2 | 42,409,680 | 00.0 |
| Scope 3 | - | - |
How Carbon Intensive is Concord Biotech's Industry?
How Carbon Intensive is Concord Biotech's Location?
Concord Biotech's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Concord Biotech has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
